Analyst EndorsementAnalyst reiterates a $90 price target and Buy rating on ARWR, with anticipation of positive outcomes in upcoming clinical trials, reflecting strong confidence in the stock's future performance.
Clinical Development ProgressEncouraging 48-week Phase 2b data support the advancement of plozasiran into a Phase 3 program, indicating a broader therapeutic potential and a significant step towards commercialization.
Pipeline PotentialArrowhead's cardiometabolic and pulmonary franchises are set to drive near-term value for shareholders, with early 2025 earmarked for its first potential commercial launch, signifying a major milestone for the company.